



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application of: Laurent F. A. HENNEQUIN | ) | Confirmation No.:9027     |
|---|---|---------------------------|
| Application No.: 10/532,958                   | ) | Group Art Unit: 1625      |
| Filed: April 27, 2005                         | ) | Examiner: Margaret SEAMAN |
| For: 3-CYANO-QUINOLINE DERIVATIVES            | ) |                           |
|   |   | Date: December 21, 2006   |
| Commissioner for Patents                      |   |                           |
| U.S. Patent and Trademark Office              |   |                           |
| Customer Window, Mail Stop Amendment          |   |                           |
| Randolph Building                             |   |                           |
| 401 Dulany Street                             |   |                           |

## **COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE**

Sir:

Alexandria, VA 22314

The following Comments on the Reasons for Allowance are being filed together with payment of the Issue Fee.

With reference to the "examiner's statement of reasons for allowance" in paragraphs 2-7 on pages 2-3 of the Notice of Allowability accompanying the Notice of Allowance mailed September 21, 2006, the undersigned **affirms the election of Group I** made during the telephone discussion with the Examiner on September 18, 2006. The Examiner has deleted non-elected claims 14-16, and it is understood that no further action is required by Applicant in the present application.

For completeness of the record, when noting the allowability of claims 1-9 in the Action mailed March 23, 2006, the Examiner stated at page 3 thereof:

Claims 1-9 are allowable over the prior art of record. The closest art is US Patent 6225318 Sobolov-Jaynes. However Sobolov-Jaynes compounds have a quinazolone core as compared to the instantly claimed quinoline core.

Applicant wishes to supplement this statement by noting that, in addition to the quinazoline/quinoline distinction noted by the Examiner, the Sobolov-Jaynes reference does not disclose the heterocyclic substituent required by the present claims at the 4-position of the quinoline ring

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockius LLR

Date: December 21, 2006 Morgan Lewis & Bockius LLP Customer No. 09629

1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001